MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 3001-3004

  Oliveira, Jaqueline C ^a   Brassesco, María S ^a   Morales, Andressa G ^a   Pezuk, Julia A ^a   Fedatto, Paola Fernanda ^a   da Silva, Glenda N ^b   Scrideli, Carlos A ^a   Tone, Luiz G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bladder carcinoma; MicroRNA 100; Tumor suppressor

Indexed keywords

EID: 84863318483     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Almeida MI, Reis RM, Calin GA. (2011). MicroRNA history: Discovery, recent applications, and next frontiers. Mutat Res, 717, 1-8.
2. Catto JW, Miah S, Owen HC, et al (2009). Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res, 69, 8472-81.
3. Filipowicz W, Bhattacharyya SN, Sonenberg N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answer sinsight? Nat Rev Genet, 9, 102-14.
4. Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C (2006). Clonogenic assay of cells in vitro. Nat Protoc, 1, 2315-9
5. Garcia JA, Danielpour D. (2008). Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther, 7, 1347-54.
6. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM. (2009). Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer, 48, 569-82.
7. Ichimi T, Enokida H, Okuno Y, et al (2009). Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer, 125, 345-52.
8. Jacobs BL, Lee CT, Montie JE. (2010). Bladder cancer in 2010: how far have we come? CA Cancer J Clin, 60, 244-72.
9. Leite KR, Tomiyama A, Reis ST, et al (2011). MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol, 185, 1118-22.
10. Li BH, Zhou JS, Ye F, et al (2011). Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer, 47, 2166-74.
11. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8.
12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8.
13. Nagaraja AK, Creighton CJ, Yu Z, et al (2010). A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol, 24, 447-63.
14. Nana-Sinkam SP, Croce CM. (2011). MicroRNAs as therapeutic targets in cancer. Transl Res, 157, 216-25.
15. Necela BM, Carr JM, Asmann YW, Thompson EA. (2011). Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/+)) models of colon cancer. PLoS One, 6, e18501.
16. Park SJ, Lee TJ, Chang IH. (2011) Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study. Korean J Urol, 52, 466-73.
17. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. (2010). Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res, 70, 36-45.
18. Saini S, Yamamura S, Majid S, et al (2011). MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res, 71, 6208-19.
19. Schedel F, Pries R, Thode B, et al (2011). mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep, 25, 763-8.
20. Shi W, Alajez NM, Bastianutto C, et al (2010). Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer, 126, 2036-48.
21. Song T, Xia W, Shao N, et al (2011). Differential miRNA expression profiles in bladder urothelial carcinomas. AsianPac J Cancer Prev, 11, 905-11.
22. Tovar V, Alsinet C, Villanueva A, et al (2010). IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol, 52, 550-9.
23. Xing L, Todd NW, Yu L, Fang H, Jiang F. (2010). Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol, 23, 1157-64.
24. Yamamoto Y, Matsuyama H, Kawauchi S, et al (2006). Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology, 70, 231-7.